Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 8/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5983341 | 0.92 | NPSR1 (0.39) | CACNA1GCACNA1BMAPK1NPSR1HTT | |
| SCHEMBL4806229 | 0.84 | NPSR1 (0.44) | CACNA1GCACNA1BMAPK1NPSR1HTT | |
| SCHEMBL14080782 | 0.78 | KCNJ1 (0.40) | SLC22A12LTA4HTRPV4AR | |
| SCHEMBL3699384 | 0.77 | OPRM1 (0.45) | MAPK1NPSR1HTTMITFLMNA | |
| SCHEMBL10535321 | 0.74 | TRPV4 (0.55) | SLC22A12TRPV4AR | |
| SCHEMBL28748012 | 0.74 | TRPV4 (0.46) | SLC22A12TRPV4AR | |
| SCHEMBL4805091 | 0.71 | OPRM1 (0.69) | CACNA1GCACNA1B | |
| SCHEMBL11963166 | 0.70 | TRPV4 (0.49) | TRPV4AR | |
| SCHEMBL20871212 | 0.70 | CHRM2 (0.64) | MAPK1NPSR1HTTMITFLMNA | |
| SCHEMBL8251673 | 0.70 | TRPV4 (0.52) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699783-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1699783-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-07-25 | — | — | EP | disclosed |
| US-7414132-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414132-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414132-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070112036-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070112036-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070112036-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112036-A1 | Opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | CACNA1G 270/4885CACNA1B 425/4885MAPK1 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.